Eucalyptal A inhibits glioma by rectifying oncogenic splicing of MYO1B mRNA via suppressing SRSF1 expression

Area of Science:

• Natural Product Chemistry
• Oncology
• Molecular Biology

Background:

• Glioblastoma (GBM) is a lethal primary brain tumor with limited effective chemotherapy options.
• Phloroglucinol-terpene adducts from Eucalyptus species are emerging as promising anti-cancer lead compounds.
• Novel therapeutic strategies are urgently needed for GBM treatment.

Purpose of the Study:

• To isolate and characterize Eucalyptal A from Eucalyptus globulus.
• To investigate the in vitro and in vivo anti-GBM activity of Eucalyptal A.
• To elucidate the molecular mechanisms underlying Eucalyptal A's anti-GBM effects.

Main Methods:

• Isolation and structural elucidation of Eucalyptal A.
• In vitro assays for GBM cell proliferation, growth, and invasion.
• In vivo studies using tumor-bearing mice models.
• Molecular mechanism studies involving gene expression and splicing analysis (SRSF1, MYO1B), and pathway analysis (PDK1/AKT/c-Myc, PAK/Cofilin).

Main Results:

• Eucalyptal A demonstrated significant inhibition of GBM cell proliferation, growth, and invasiveness in vitro.
• In vivo, Eucalyptal A exhibited anti-GBM activity, prolonged survival, and maintained body weight in tumor-bearing mice.
• Eucalyptal A was found to downregulate SRSF1 expression and correct aberrant MYO1B mRNA splicing via specific signaling pathways.

Conclusions:

• Eucalyptal A is identified as a potent anti-GBM lead compound with potential therapeutic applications.
• The compound exerts its anti-GBM effects by modulating SRSF1 expression and downstream signaling pathways.
• Eucalyptal A represents a novel therapeutic avenue for glioma treatment.